The recommendations highlighted the use of immunosuppressive agents and antifibrotics to treat skin fibrosis and lung fibrosis, as well as changes to upfront treatment of pulmonary hypertension.
VIENNA — The use of immunosuppressive and antifibrotic drugs to treat skin and lung fibrosis leads updated recommendations from the European Alliance of Associations for Rheumatology for the treatment of systemic sclerosis .
A slide showing the different strengths of evidence for various drugs across the eight manifestations illustrated the principle behind the therapeutic continuums."These 'therapeutic continuums' suggest a common pathogenetic mechanism driving the various manifestations of disease," said Del Galdo.
Del Galdo stressed that the complex nature of systemic sclerosis means that"when thinking of treating one manifestation, you also always need to consider all the other clinical manifestations as experienced by the patient, and it is this multifaceted scenario that will ultimately lead to your final choice."
He also pointed out that selexipag and riociguat were new and important second-line additions for the treatment of PAH, and —consistent with the ERA approach — the EULAR recommendation supports frequent follow-up to establish a treat-to-target approach to maximizing clinical outcomes in SSc-PAH and SSc-ILD."Specifically, for the first time, we recommend monitoring the effect of any chosen intervention selected within 3-6 months of starting.
"We definitely are one step forward compared to this 2017 recommendation and closer to what we would like to do," he asserted.In some respects, according to Del Galdo, research and development is making relatively slow progress, especially compared with other rheumatologic diseases such as rheumatoid arthritis."We cannot put patients with systemic sclerosis in remission yet.
Crest Syndrome Pulmonary Arterial Hypertension PAH - Pulmonary Arterial Hypertension PAH Lung Fibrosis Pulmonary Fibrosis Lung Treatment Guidelines Interstitial Lung Disease Systemic Sclerosis Diffuse Scleroderma Heart Failure Hypertension Biologic Therapy Biologics Idiopathic Pulmonary Fibrosis IPF Idiopathic Pulmonary Fibrosis (IPF) IPF - Pulmonary Fibrosis Remission
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Anti-Ro/SSA Antibodies Have Potential to Predict ILD in Systemic SclerosisAnti-Ro/SSA antibodies predicted which patients were at most risk for ILD but not ILD progression or overall disease progression and death.
Read more »
Mechanisms for selective multiple sclerosis treatment strategyResearchers have demonstrated how B cells infected with the Epstein-Barr virus (EBV) can contribute to a pathogenic, inflammatory phenotype that contributes to multiple sclerosis (MS); the group has also shown how these problematic B cells can be selectively targeted in a way that reduces the damaging autoimmune response of multiple sclerosis.
Read more »
Dealing with decline from multiple sclerosisAs a multiple sclerosis patient ages, their condition may stop responding to regular treatment.
Read more »
Multiple Sclerosis Med Nearly Eliminates Disease Activity on MRIA second-generation anti-CD40L monoclonal antibody suppresses multiple sclerosis (MS) disease activity on MRI to an uncommonly high degree, new trial data suggested.
Read more »
Selma Blair Shared a Heartwarming Update on Her Multiple Sclerosis RemissionSelma Blair spoke about her multiple sclerosis remission and explained how she's happy about fellow patients Christina Applegate and Jamie-Lynn Sigler sharing their own experiences with MS on their podcast, 'MeSsy.'
Read more »
Epstein-Barr Virus and brain cross-reactivity: possible mechanism for Multiple SclerosisThe role that Epstein-Barr Virus (EBV) plays in the development of Multiple Sclerosis may be caused a higher level of cross-reactivity, where the body's immune system binds to the wrong target, than previously thought.
Read more »